.jetcityimage/iStock Editorial by means of Getty Images Morgan Stanley has actually chosen Eli Lilly (NYSE: LLY) as its own leading biopharma pick for 2025 and measured another 9 titles in the room as obese. The investment bank said in a keep in mind that it remains to strongly believe “diabesity is set to end up being.